MonTa Biosciences has successfully gone through a tough selection process and been enrolled into the Nanotechnology Characterization Laboratory (NCL) program under the National Cancer Institute (NCI) in the US. Our lead candidate MBS8 has been selected for the NCL program where NCL free of charge will support MonTa with additional Mode of Action studies to advance our development towards phase I/IIA trial in cancer patients. We are very exited about this collaboration and look forward to work together with NCL towards improving cancer treatment of patients in need.Press Release September 2020 MonTa-NCL collaboration version 2.0 Final
